Lebrikizumab is a recombinant humanized monoclonal antibody designed to selectively target interleukin-13 (IL-13), a key cytokine involved in type 2 inflammatory responses. It is an advanced biological active pharmaceutical ingredient developed for the treatment of inflammatory diseases, particularly moderate-to-severe atopic dermatitis.
Lebrikizumab binds with high affinity to IL-13 and prevents IL-13 from interacting with its receptor complex. By inhibiting IL-13 signaling, Lebrikizumab helps reduce downstream inflammatory responses associated with type 2 inflammation and the pathophysiology of atopic dermatitis.
Lebrikizumab is a humanized IgG4 monoclonal antibody produced using recombinant DNA technology in a mammalian cell expression system. As a biologic molecule, it is substantially different from conventional small-molecule APIs and is characterized using a range of physicochemical, biochemical and biological analytical methods.
Its approximate molecular mass is 150 kDa, although the exact molecular mass can vary because of post-translational modifications, including glycosylation.
Lebrikizumab selectively binds to IL-13, preventing IL-13 from signaling through the IL-4 receptor alpha (IL-4Rα)/IL-13 receptor alpha 1 (IL-13Rα1) receptor complex.
IL-13 is an important mediator of type 2 inflammation and contributes to immune dysregulation, epidermal barrier abnormalities and other inflammatory processes. Blocking IL-13 signaling reduces this inflammatory pathway and provides a targeted therapeutic approach for atopic dermatitis.
Lebrikizumab is used for the treatment of moderate-to-severe atopic dermatitis in appropriate patients according to applicable approved indications.
It is administered as a subcutaneous injection and may be used alone or with topical corticosteroids, depending on the approved treatment regimen.
As a monoclonal antibody, Lebrikizumab requires extensive characterization beyond the conventional testing used for small-molecule APIs.
Analytical evaluation may include identity, purity, aggregation, charge variants, glycosylation profile, protein concentration, biological activity, host-cell proteins, residual host-cell DNA, residual process-related impurities, endotoxin, bioburden and sterility-related attributes where applicable.
Suitable techniques can include size-exclusion chromatography (SEC), ion-exchange chromatography (IEX), peptide mapping, mass spectrometry, capillary electrophoresis and cell-based biological assays.
Acceptance criteria should be based on the applicable approved biological drug-substance specification, Certificate of Analysis and regulatory requirements.
Lebrikizumab should be stored under controlled cold-chain conditions appropriate for a recombinant monoclonal antibody. It should generally be protected from light and should not be frozen unless specifically permitted by the applicable manufacturer's specification.
Specific storage temperature, handling and transportation requirements should follow the approved product or drug-substance specification.
Lebrikizumab is a high-value biological API intended for qualified pharmaceutical and biopharmaceutical development and manufacturing applications. Product specifications, analytical documentation, Certificate of Analysis, batch information, storage conditions and regulatory documentation should be confirmed according to the intended application.
Lebrikizumab biological API is available for qualified pharmaceutical and biopharmaceutical development requirements subject to applicable regulatory and quality requirements. Customers can request product specifications, analytical documentation, Certificate of Analysis, packaging information and commercial details for their specific requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |